Trial Profile
Effectiveness and Safety of Apatinib for the Patients With Advanced Soft Tissue Sarcoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jun 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Alveolar soft part sarcoma; Clear cell sarcoma; Ewing's sarcoma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Results (n=35, Data cut off: Jan 16, 2018) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 12 Sep 2017 Results (n=6) assessing efficacy and safety, presented at the 42nd European Society for Medical Oncology Congress.